Chemfab Alkalis Limited has informed the Exchange regarding 'Investor Presentation for quarter and year ended 31.03.2025'.
CHEMFAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemfab Alkalis reported FY25 revenue of ₹322.09 cr (down 1.6% YoY) and PAT of ₹15.22 cr (down ~49% YoY), with EBITDA margin contracting to 16.54% from 17.61% in FY24. Q4FY25 showed recovery, with revenue up 7% YoY to ₹87.85 cr and EBITDA up 19% YoY to ₹15.68 cr, driven by chlor-alkali ECU realisations rising to ₹42,386 from ₹34,016 in Q4FY24. The chlor-alkali segment swung to a Q4 profit with EBITDA margin expanding 410 bps YoY to 9.44%, while OPVC Pipes saw revenue dip 10% YoY to ₹31.53 cr due to delayed government fund releases under Jal Jeevan Mission. Key strategic updates include OPVC capacity expansion from 14,000 TPA to 23,000 TPA in FY26, ₹60 cr investment in chlor-alkali technology modernisation, and a hybrid power project expected in Q2FY26 to reduce power costs. The Board approved sale of 667.49 acres of surplus land (FY26) and a ₹9.88 cr write-off of the deferred Karaikal caustic soda project.
Margin improvement guidance from the hybrid power project (Q2FY26) and stable ECU realisations are positive signals for FY26 profitability, while the OPVC segment's capacity expansion (65% increase) positions the company to benefit from extended Jal Jeevan Mission demand. Short-term, the land sale and asset write-off clean up the balance sheet, though rising debt (long-term borrowings up to ₹63.80 cr) and finance costs (₹1.56 cr in Q4 vs ₹0.41 cr YoY) warrant attention.